

Product List

Molecule	Strength	Presentations	Indication / Therapy Class	Status of Dossier
Atosiban	7.5 mg/ml Solution for Injection/Infusion	6.75 mg/0.9ml Vial 37.5mg/5ml Vial 75 mg/10ml Vial	<ul style="list-style-type: none"> • Delay imminent pre-term birth in pregnant adult women • Unique 10 ml vial 	Currently registered in majority of EU countries
Azacitidine	25 mg/ml Powder for Suspension for Injection	100 mg Vial 150 mg Vial	<ul style="list-style-type: none"> • Treatment of adult patients who are not eligible for HSCT with MDS, CMML, and AML 	Currently registered in majority of EU countries
Cabazitaxel	10 mg/ml Solution for Infusion	45 mg/4,5ml Vial 50 mg/5ml Vial 60 mg/6 ml Vial	<ul style="list-style-type: none"> • Treatment of adult patients with mCRPC previously treated with a docetaxel containing regimen in combination with prednisone or prednisolone 	Currently registered in majority of EU countries and AU
Cerebrolysin®	215.2 mg/ml Solution for Infusion Concentrate for Solution for Infusion	215.2 mg/1 ml Ampoule 430.4 mg/2 ml Ampoule 1.08 g/5 ml Ampoule 2.2 g/10 ml Ampoule 4.3 g/20 ml Vial 6.5 g/30 ml Vial 10.8 g/50 ml Vial	<ul style="list-style-type: none"> • Senile dementia of Alzheimer's type • Vascular dementia • Craniocerebral trauma (commotio and contusio) • Stroke 	49 national registrations
Dacepton® Dopaceptin® Apomine™ (Apomorphine)	5 mg/ml & 10 mg/ml Solution for Injection/Infusion	50 mg/5 ml Ampoule 100 mg/20 ml Vial 30 mg/3 ml Cartridge	<ul style="list-style-type: none"> • Treatment of motor fluctuations ("on-off" phenomena) in patients with Parkinson's disease which are not sufficiently controlled by oral anti-Parkinson medication 	Approved in majority of EU countries, Australia, New Zealand
Dexmedetomidine	100 µg/ml Concentrate for Solution for Infusion	200 µg/2 ml Ampoule 400 µg/4 ml Ampoule 1,000 µg/10 ml Ampoule 200 µg/2 ml Vial 400 µg/4 ml Vial 1,000 µg/10 ml Vial	Anaesthetic: <ul style="list-style-type: none"> • ICU adult sedation • First EU Dexmedetomidine approved for Procedural sedation 	Currently registered in majority of EU countries, CIS, and Australia
Docetaxel	20 mg/ml Concentrate for injection	20 mg/1 ml Vial 80 mg/4 ml Vial 160 mg/8 ml Vial	<ul style="list-style-type: none"> • Cytostatic with multiple indications incl. breast cancer, pro- state cancer, et.al. 	Registered in DE Registration planned for other countries
Fulvestrant	50 mg/ml Ready to use pre-filled syringe	250 mg/5 ml PFS	<ul style="list-style-type: none"> • Treatment of locally advanced or metastatic breast cancer • First Fulvestrant approved for storage at room temperature 	Currently registered in majority of EU countries, CIS, AU, and selected ME markets
Oxytocin	5 IU/ml & 10 IU/ml Solution for Injection/Infusion	5 IU/1 ml Ampoule 10 IU/1 ml Ampoule	<ul style="list-style-type: none"> • Stimulates labour in hypotonic uterine inertia during caesarean section • Prevention and treatment of post- partum uterine atony and haemorrhage 	Approved in UK and FR
Paclitaxel	6 mg/ml Concentrate for Injection	30 mg/5 ml Vial 100 mg/16.7 ml Vial 300 mg/50 ml Vial	<ul style="list-style-type: none"> • Cytostatic with multiple indications incl. breast cancer, pro- state cancer, et.al. 	Registered in DE Registration planned for other countries
Pemetrexed	25 mg/ml Concentrate for Solution for Infusion	100 mg/4 ml Vial 500 mg/20 ml Vial 1,000 mg/40 ml Vial	<ul style="list-style-type: none"> • Treatment of malignant pleural mesothelioma and locally advanced or metastatic nonsquamous NSCLC 	Registered in majority of EU markets
Terlipressin	0.17 mg/ml Solution for Injection/Infusion	0.85 mg/5 ml Vial 1.7 mg/10 ml Vial	<ul style="list-style-type: none"> • Bleeding esophageal varices • Unique 10 ml vial 	Currently registered in majority of EU countries

EPL/INT/10/2021/1